Randomized trials tell us what happened in the trial. But how far can those findings extend into routine care?
We are pleased to share a new paper in Epidemiology, first-authored by our colleague Jessica Young.
Using data from VALIDATE-SWEDEHEART and Swedish healthcare […]
Last week, our Senior Project Lead, Kelsi Smith, was invited to speak at the Singapore Clinical Research Institute (SCRI) Clinical Trials Symposium 2026.
Kelsi joined the session […]
Kirk Geale, PhD and Jessica Young will represent Quantify Research at the 42nd ISPE Annual Meeting, from 29 August to 2 September 2026.
This year’s theme, Unlocking the Power of Pharmacoepidemiology to Improve […]
We are pleased to share that Kelsi Smith, Senior Project Lead, Real-World Evidence and Analytics at Quantify Research, will be speaking at the Singapore Clinical Research Institute (SCRI) Trials Symposium 2026 in Singapore.
Kelsi will […]
Our Market Access Strategy unit recently held a workshop focused on Joint Clinical Assessment (JCA) learnings.
The session brought together perspectives from Quantify Research and our sister companies within the athagoras Group creating a valuable opportunity to learn from practical experience […]
We are pleased to welcome Pankaj Khajuria as a Research Analyst in our Evidence, Review and Synthesis unit Quantify Research India.
Pankaj first joined Quantify Research as an ERS Intern where he contributed to systematic literature reviews, evidence synthesis, and HEOR […]
A good week in evidence, access, and collaboration.
Last Monday, 22 June, we had the pleasure of hosting Giuseppe Pileggi, CEO of athagoras, for the athagoras Townhall in Stockholm.
It was a valuable opportunity […]
TLV has published new general guidelines and version 7.0 of its handbook for pharmaceutical reimbursement and pricing applications. TLV’s new general guidelines and application regulations apply from 1 October 2026. For market access teams, this is not a methodological reset. […]
We are pleased to share that our new publication, developed in partnership with the IFPA International Federation of Psoriasis Associations, ” Economic Impact of Timely Systemic Treatment of Psoriatic Disease in Comorbidity Risk Reduction”, […]
The first Joint Clinical Assessment report under the EU HTA Regulation is now published. It covers Ojemada® / tovorafenib, for paediatric low-grade glioma.
Across the Nordics, the message from national HTA agencies is consistent:
Do not resubmit clinical evidence already available through […]